Skip to content

Nymox to file for 1st in class prostate med in Europe, with call May 10

May 8, 2017

Nymox Pharmaceutical Corporation (NYMX) Following Nymox’s announcement of the Company’s filing for marketing approval of Fexapotide Triflutate for enlarged prostate (BPH) in Europe, Nymox is pleased to announce a teleconference with shareholders at 4:30 p.m. EDT on Wednesday May 10, 2017. The call-in number will be reported prior to the teleconference call.

Shareholder questions in advance are welcomed and can be sent by email to:


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: